Amivantamab-chemotherapy demonstrates longest overall survival reported for lung cancer with EGFR mutation
Results from the phase 3 PAPILLON study show that first-line amivantamab plus carboplatin-pemetrexed (amivantamab-chemotherapy) was associated with numerically longer overall survival compared with chemotherapy in patients with previously untreated advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (Ex20ins) mutations. The findings were presented at the International…
A new study has revealed that first-line treatment with amivantamab-chemotherapy, combined with carboplatin-pemetrexed, resulted in longer overall survival for patients with advanced non-small cell lung cancer (NSCLC) carrying EGFR exon 20 insertion (Ex20ins) mutations compared to standard chemotherapy. The research, presented at the 2026 International Association for the Study of Lung Cancer World Conference on Lung Cancer, analyzed 308 participants in the PAPILLON study.
The adjusted analysis indicated a significant survival benefit of 6.4 months with amivantamab-chemotherapy, and continued to show favorability even after accounting for patients who crossed over to second-line amivantamab monotherapy.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
